Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: The IGCS-COL multicentre, randomised, phase III study

British Journal of Cancer

Volumn 93, Issue 8, 2005, Pages 896-904

  De Placido, S ^a   Lopez, M ^b   Carlomagno, C ^a   Paoletti, G ^b   Palazzo, S ^c   Manzione, L ^d   Iannace, C ^e   Ianniello, G P ^f   De Vita, F ^g   Ficorella, C ^h   Farris, A ⁱ   Pistillucci, G ^j   Gemini, M ^k   Cortesi, E ^l   Adamo, V ^m   Gebbia, N ⁿ   Palmeri, S ⁿ   Gallo, C ^g   Perrone, F ^o   Persico, G ^a   Bianco, A R ^a   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Mariano Santo Hospital   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f ASL   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h UNIVERSITY OF L'AQUILA   (Italy)

ⁱ UNIVERSITY OF SASSARI   (Italy)

^j SANTA MARIA GORETTI HOSPITAL   (Italy)

^k BELCOLLE HOSPITAL   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m UNIVERSITY OF MESSINA   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

5 fluorouracil modulation; Adjuvant chemotherapy; Colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; MITOMYCIN C;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEATH; DIARRHEA; DRUG FATALITY; EYE TOXICITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HISTOLOGY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN DEFECT; STOMACH ULCER; SURVIVAL; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT PLANNING; VASCULAR DISEASE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEVAMISOLE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 27144439057     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602800     Document Type: Article

References (25)

1. Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Andrè T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, De Gramont A (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant traetment for colon cancer. N Engl J Med 35: 2343-2351
3. Arkenau HT, Bermann A, Retting K, Strohmeyer G, Porschen R, on behalf of the Arbeitsgemeinschaft Gastrointestinale Onkologie (2003) 5-Fluorouracil plus Leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCa-01 trial. Ann Oncol 14: 395-399
4. Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figuerado AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charrette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 1-12
5. Bleeker WA, Mulder NH, Hermans J, Otter R, Plukker JT, for the IKN Colon Trial Group (2000) The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. Ann Oncol 11: 547-552
6. Cascinu S, Catalano V, Piga A, Mattioli R, Marcellini M, Pancotti A, Bastioni R, Torresi U, Silva RR, Pieroni V, Giorni F, Catalano G, Cellerino R (2003) The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomised trial of 5-fluorouracil and levamisole vs 5-fluorouracile alone. Cancer Invest 21: 701-707
7. Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Brizzi P, Lippi G, Gallo L, Conte P, Comandone A, Turci D, Mrzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R (2003) Adjuvant chemotherapy in the treatment of colon cancer: randomised multicentre trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol 14: 1365-1372
8. Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free interval in surgically treated rectal cancer carcinoma. N Eng J Med 312: 1465-1472
9. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF, Veeder MH, Witzig TE, Cha S, Vidyarti SC (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324: 709-715
10. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh J, Rubin J, McCormack GW, Gersten JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447-1456
11. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
12. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
13. NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450
14. O'Connell M, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand S, Rubin J, Vukov AM, Donohue JH, Krook JE, Figuerado A (1998) Prospectively randomised trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295-300
15. Panettiere FJ, Goodman PJ, Costanzi JJ, Cruz AB, Vaitkevicius VK, McCracken JD, Brownlee RW, Laufman L, Stephens RL, Bonnet J, Bottomley R, Rivkin S, Fletcher W, Oishi N, Chen TT (1988) Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol 6: 947-954
16. Porschen R, Bermann A, Loffler T, Haack G, Retting K, Anger Y, Strohmeyer G, for the the Arbeitsgemeinschaft Gastrointestinale Onkologie (2001) Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCa-01. J Clin Oncol 19: 1787-1794
17. Quasar Collaborative Group (2000) Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355: 1588-1596
18. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14: 1735-1743
19. Smalley SR, Benedetti J, Williamson S, Robertson J, Fisher B, Martenson J, Benson AB, Robert M, Cripps C, MacDonald J, for the SWOG (2003) Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer* Bolus 5FU vs prolonged venous infusion before and after XRT+PVI vs bolus 5FU+leucovorin+levamisole before and after XRT+bolus 5FU+LV. Proc Am Soc Clin Oncol 22: 251 (abstr 1006)
20. Taal BG, Van Tinteren H, Zoetmulder F, on behalf of the NACCP Group (2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85: 1437-1443
21. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson III AB, Cummings B, Gunderson LL, MacDonald JS, Martenson JA, Mayer RJ (2002) Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - Final report of Intergroup 0114. J Clin Oncol 20: 1744-1750
22. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon caner. New Engl J Med 352: 2696-2704
23. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337-1345
24. Wolmark N, Rockette H, Fisher B, Wickeram DL, Redmond C, Fisher ER, Jones J, Mamounas E, Ore L, Petrelli NJ, Spurr CL, Dimitrov NV, Romond EH, Sutherland CM, Kardinal CG, De Fusco PA, Jochimsen P (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from NSABP Protocol C-03. J Clin Oncol 11: 1879-1887
25. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickeram DL, Bear HD, Aktins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of flourouracil and leucovorin, flourouracil and levamisole, and flourouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from NSABP-C-04. J Clin Oncol 17: 3553-3559